Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jane-Frances Shiti

Nurse Practitioner, Family Albuquerque, NM Nurse Practitioner

NPI 1215461629 CMS profile 10508347

3500 Comanche Rd Ne Ste 1, Albuquerque, NM 87107

Open in the dashboard

General payments

$1,141

33 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jane-Frances Shiti of Albuquerque, NM is reported in the CMS Open Payments database as having received $1,141 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $144 6
2024 General $335 15
2023 General $431 9
2022 General $230 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane-Frances Shiti
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jane-Frances Shiti were reported at $144. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jane-Frances Shiti Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $230 $141 $44–$430 $149
2023 $431 $154 $49–$476 $160
2024 $335 $165 $51–$504 $164
2025 $144 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Neurocrine Biosciences, Inc. $400 16 payments
  2. Alkermes, Inc. $307 3 payments
  3. Sanofi-Aventis U.S. LLC $124 1 payment
  4. Otsuka America Pharmaceutical, Inc. $101 4 payments
  5. Teva Pharmaceuticals USA, Inc. $94 4 payments
  6. AbbVie, Inc. $47 2 payments
  7. ITI, Inc. $28 1 payment
  8. Janssen Pharmaceuticals, Inc $23 1 payment
  9. E.R. Squibb & Sons, L.L.C. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,141 33 payments
Products named General payments · program years 2022–2025
  1. INGREZZA $400 16 payments
  2. LYBALVI Cns $307 3 payments
  3. LYBALVI Cns $307 3 payments
  4. LYBALVI Cns $307 3 payments
  5. LYBALVI Cns $307 3 payments
  6. SOLIQUA 100/33 $124 1 payment
  7. REXULTI $101 4 payments
  8. UZEDY $94 4 payments
  9. VRAYLAR $47 2 payments
  10. CAPLYTA $28 1 payment
  11. Other $40 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

574

Median for Nurse Practitioner: 389

Drug cost

$46,762

Median for Nurse Practitioner: $21,885

Branded share of claims

15.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 12 $18,835
Eliquis Apixaban Brand 26 $7,685
Xarelto Rivaroxaban Brand 22 $6,448
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 14 $4,179
Memantine Hcl Generic 24 $1,890
Atorvastatin Calcium Generic 52 $1,153
Carvedilol Generic 36 $891
Trazodone Hcl Generic 43 $649
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $588
Levothyroxine Sodium Generic 46 $558

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$6,124

Medicare's payments for the services billed

Medicare patients

74

Average age 74

Services billed

130

45 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Alzheimer's or dementia 54%
Diabetes 38%
Arthritis 34%
Chronic kidney disease 24%
COPD 22%
Ischemic heart disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $104
$104 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $79
$79 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $54
$54 — —
VRAYLAR
  • AbbVie, Inc. $47
$47 — —
CAPLYTA
  • ITI, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record